Dr. Neetu Saxena received her master’s in Biotechnology from Indian Institutes of Technology-Roorkee, India followed by Ph.D. from Jawaharlal Nehru University, India in Molecular Biology and Biochemistry. During her Ph.D., she engineered D-Hydantoinase, an industrial enzyme, to increase its activity towards non-natural substrates. She then completed her postdoctoral training at National Institutes of Health, USA where she performed first metabolic characterization of Succinate dehydrogenase subunit B (SDHB)-mutated kidney cancer. She applied her expertise in cancer metabolism field in her next role as a research associate at Vancouver prostate Centre and identified a novel crosstalk between succinate dehydrogenase and androgen receptor, the major driver of prostate cancer and introduced a combination therapy to overcome treatment resistance in prostate cancer. She later established a new translational research laboratory at Vancouver Prostate Centre as Project Manager and managed multiple immune-oncology projects for biomarker development. She joined as a Translational Scientist in Hale Family of Pancreatic Cancer at Dana Farber Cancer Institute in 2023.